A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 4 (2) , 138-141
- https://doi.org/10.3816/cbc.2003.n.019
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Docetaxel in the treatment of breast cancer: An update on recent studiesSeminars in Oncology, 2002
- Clinical experience of capecitabine in metastatic breast cancerEuropean Journal Of Cancer, 2002
- Breast Cancer: Single Agents ChemotherapyTumori Journal, 2002
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancerAnnals of Oncology, 2001
- Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter TrialJournal of Clinical Oncology, 2001
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.Journal of Clinical Oncology, 1998
- Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer.Journal of Clinical Oncology, 1994
- The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.Journal of Clinical Oncology, 1987